ReNewVax logo
Vaccines
Venture roundlatest round · Dec 2025 · 10 mo ago
1backers · SFC Capital
2022founded
10stories in the press
Overview
Protecting Our Future. ReNewVax is a next-generation bacterial vaccine company developing the first universal vaccine targeting all ca.100 existing variants of S. pneumoniae, or pneumococcal, bacteria.
Official records
Funding and backers
Latest round
Venture round
Dec 2025 · 10 mo ago
Backers
1
SFC Capital
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 24, 2025
Raised a round Venture round
Jul 18, 2025
Raised a round Venture round
Oct 18, 2024
Raised a round Venture round
Apr 30, 2024
Raised a round Venture round
May 9, 2022
Raised a round Venture round
2022
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Dec 2025 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Jul 2025 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Oct 2024 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | Apr 2024 | — | — | find-and-update.company-information.service.gov.uk |
| Venture round | May 2022 | — | — | find-and-update.company-information.service.gov.uk |
Registers and programsofficial lists and records that name the company
| Legal entity | ReNewVax Ltd. | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Transforming global healthcare with self-administered microneedle vaccine patches. Safe, efficient, and accessible- bringing vaccinations…
Innovators in natural vaccine technology. Explore rapidly engineered, scalable vaccine technologies at Hexamer Therapeutics.
Calder Biosciences is a nano-scale molecular engineering company developing next generation best-in-class conformationally-stabilized…
404 Err….or The vaccines you're looking for don't exist. Yet….
Animal Vaccine Delivery in Just 30 Minutes. Experience the world's fastest vaccine delivery. Get a complete range of vaccines delivered…
GIVAX is developing a new class of vaccines to protect children from severe gastroenteritis caused by rotavirus and norovirus. Leveraging…
Financials
Latest round
Venture - Series Unknown
Funding rounds
5
People
Neil Murray
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
SFC CapitalVia a fund
468 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
ReNewVax Showcases Universal Pneumococcal Vaccine Vision at BIO-Europe 2025
At BIO-Europe 2025 in Vienna, ReNewVax CEO Neil Murray sat down with BiotechTV's Amy Brown to share how the company is advancing a next-generation, low-cost universal pneumococcal vaccine, targeting all 100 known serotypes of Streptococcus pneumoniae. "We
Read more
Report
ReNewVax CEO Publishes Feature in Pharmaphorum
We're proud to share that ReNewVax CEO, Neil Murray, had his article published in Pharmaphorum, addressing one of the most urgent global health challenges of our time, antimicrobial resistance (AMR). Titled "When is the superbug message going to bite?", t
Read more
Report
ReNewVax News: Appointment of Simon Thorn as CFO
ReNewVax are pleased to announce the appointment of Simon Thorn as Chief Financial Officer. An accomplished senior executive with significant expertise in the venture capital sector working hands-on with SME's to help them to scale, prior to joining ReNew
Read more
Report
Spotlight on Northern Life Sciences in City AM
ReNewVax has been included in the "Northern Life Sciences" supplement published by City AM. The supplement shines a spotlight on the achievements of the sector in the North, with features on this year's Bionow Award winners and the important role that Bio
Read more
Report
ReNewVax named Start-up of the Year at 2024 Bionow Awards
We were delighted to receive the award for Start-up of the year at last night's Annual Bionow Awards Dinner. Commenting on the award, Neil Murray, ReNewVax's CEO, said, "It's a great honour to receive the Bionow Start-up of the Year Award. This is testame
Read more
Report
ReNewVax News: Management Changes
ReNewVax are pleased to announce the appointment of Dr Miguel Leon-Rios as Head of Research. An experienced immunologist, Miguel has been intimately involved in the translational development of our lead program RVX-001, both during his time at the Univers
Read more
Report
ReNewVax News: Company Board Appointments
ReNewVax are pleased to announce the appointment of Dr Simon Cruwys and Dr. Carolyn Horrocks to the Board of the Company. With over 30 years experience in academic and industrial research, Simon has been involved with ReNewVax since its inception. As Head
Read more
Report
BioInfect 2024: ReNewVax marks decade since O'Neill Review on AMR
ReNewVax is proud to participate in BioInfect 2024, a major conference set to commemorate the ten-year anniversary of the influential O'Neill Review on AMR. Hosted at The Spine in Liverpool's Knowledge Quarter, the event will bring together key figures fr
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Liverpool
United Kingdom
HQ